By June 8, 2009, Raptiva will no longer be available in the United States.
Genentech and FDA notified healthcare professionals of the voluntary, phased withdrawal of Raptiva, a medication for treatment of psoriasis, from the U.S. market due to a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML).
On 02/19/2009 the FDA issued [...]

Johnson & Johnson drug ustekinumab may raise the risk of cancer, the U.S. Food and Drug Administration warned Friday.
“Due to the mechanism of action of ustekinumab … there is a biologic plausibility for enhanced carcinogenic risk. Formal two-year systemic carcinogenicity studies have not been conducted with ustekinumab.’ said the FDA review material for an FDA [...]